Abstract
Obesity is characterized by systemic lipid accumulation, inflammation, and enhanced tumorigenesis in different
tissues, including colon. With obesity, intracellular lipid droplets (LDs) are accumulated in fat storing and non-fat
storing tissues. These organelles are increased in colonic tumors relative to normal tissues and may be one the
explanation for how obesity facilitates colonic tumorigenesis. As obesity is becoming a worldwide epidemic, it is
more important than ever to elucidate the tumorigenic processes mediated by LDs dynamics (lipogenesis and
lipolysis). This will provide conceptual advances in our understanding of how obesity promotes inflammatory
colonic tumorigenesis, and it will drive exploration of critical mechanisms of metabolic reprogramming within
tumorigenesis necessary for the development of effective treatment options.
We identified a self-reinforcing negative regulatory loop of LDs with the FOXO3 transcription factor involving
signaling between transcriptional and metabolic pathways that facilitates colonic inflammation and
tumorigenesis. In the proposed project, we will investigate how this regulatory network is reinforced through
acyltransferases 1/2 (DGATs) mediated lipogenesis in facilitating tumorigenesis in obesity. Our preliminary data
show that DGATs levels are elevated in human and mouse colonic tumors relative to normal (with even higher
levels in obese individuals and HFD-obese mice). Elevated DGAT2 transcripts are linked to poor patient survival.
This increase in DGATs levels also promotes LDs utilization through adipose triglyceride lipase (ATGL). The
expression of DGATs is induced by obesity and inflammatory mediators in colonic cells and is possibly regulated
by Myc that is also activated in the colon of FOXO3 deficient and HFD-obese mice. Inhibition of DGATs in human
colonic transformed cells blocks the pathway responsible for loss of FOXO3 (PI3K), lowers LDs/ATGL, and
attenuates cell growth. We hypothesize that elevated DGATs drive an LD and FOXO3 self-reinforcing loop,
blockade of which effectively shuts down this metabolic inflammatory and tumorigenic pathway. Establishing this
novel mechanism will have diagnostic and therapeutic significance in colonic tumorigenesis, especially those
driven by inflammatory obesity. The proposed project will elucidate DGATs-mediated metabolic mechanisms
stimulating colonic cell growth (Aim 1), it will identify the impact of targeting DGATs in attenuating colonic
tumorigenesis (driven by mutation and inflammation in HFD-obesity) and the associated remodeling of the
immune cell landscape (PMN, MF), molecular pathways (Myc, PI3K), and transcriptome (Aim 2), and it will
assess the significance of the DGAT-dependent LD dynamics in human colonic tumorigenesis (advanced,
inflammatory, and obesity-associated tumors) of local and TCGA patients (Aim 3).
These investigations will provide key mechanistic insights into DGAT-mediated transcriptional and metabolic
reprograming in colonic tumorigenesis and establish a solid platform for the development of novel effective
pharmacological treatments for colonic inflammation, tumorigenesis, and other HFD-related disorders.